Cross Cancer Institute

Alberta Health Services

Edmonton, AB

Accepting patients

DREAMM9

A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Randomization
  • Phase 1

Not yet accepting

EMBRACE

A Study of Elranatamab Management With Outpatient and Intermittent Dosing in Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3